Compare CTNT & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | CLDI |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.6M |
| IPO Year | 2023 | N/A |
| Metric | CTNT | CLDI |
|---|---|---|
| Price | $1.38 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.8K | ★ 324.9K |
| Earning Date | 03-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $235.67 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $1.03 | $0.22 |
| 52 Week High | $2.12 | $7.32 |
| Indicator | CTNT | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 20.67 |
| Support Level | $1.36 | $0.22 |
| Resistance Level | $1.54 | $0.90 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 11.11 | 9.02 |
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: cargo storage, freight forwarding, U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.